An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The main goal of this study is to test two new radioactive drugs,
4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and
3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in human subjects with congestive
heart failure.
Evaluations of these imaging agents will include their uptake in heart, lungs and liver,
their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies,
the better of the two drugs will be chosen for further studies in patients with heart
disease. After the better compound is chosen, additional measures of its imaging properties,
metabolism and pharmacokinetics will be done in subjects with heart failure.